Moreover, eupatilin exhibited the capacity to block epithelial-mesenchymal transition (EMT) by boosting E-cadherin levels and lowering the expression of N-cadherin (N-cad) and Vimentin in mice, which indicates that eupatilin could be a potential therapeutic choice for nasal polyp-associated chronic rhinosinusitis (31). Here, CDH2 is linked to Nasal polyposis.